M. Colombino, M. Capone, and A. Lissia, BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma, J Clin Oncol, vol.30, pp.2522-2529, 2013.

A. K. Salama and K. T. Flaherty, BRAF in melanoma: current strategies and future directions, Clin Cancer Res, vol.19, pp.4326-4334, 2013.

J. C. Rubinstein, M. Sznol, and A. C. Pavlick, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032, J Transl Med, vol.14, p.67, 2010.

L. Boursault, V. Haddad, and B. Vergier, Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing, PLoS ONE, vol.8, p.70826, 2013.

K. J. Busam, C. Hedvat, M. Pulitzer, A. Von-deimling, and A. A. Jungbluth, Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions, Am J Surg Pathol, vol.37, pp.413-420, 2013.

E. Colomba, Z. Elias-rodzewicz, V. Deimling, and A. , Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013.

J. K. Feller, S. Yang, and M. Mahalingam, Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma, Mod Pathol, vol.26, pp.414-420, 2013.

V. Hofman, M. Ilie, and E. Long-mira, Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients, J Invest Dermatol, vol.133, pp.1378-1381, 2013.

M. A. Ihle and J. Fassunke, Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014.

G. V. Long, J. S. Wilmott, and D. Capper, Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, pp.61-65, 2013.

L. L. Ritterhouse and J. A. Barletta, BRAF V600E mutation-specific antibody: a review, Semin Diagn Pathol, vol.pii, issue.15, pp.11-19, 2015.

M. Ilie, S. Lassalle, and E. Long-mira, Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in papillary thyroid carcinoma. Comparative analysis with three DNA-based assays, Thyroid, vol.24, pp.858-866, 2014.

D. Pekin, Y. Skhiri, and J. C. Baret, Quantitative and sensitive detection of rare mutations using droplet-based microfluidics, Lab Chip, vol.11, pp.2156-2166, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02148770

V. Hofman, M. Ilie, and E. Long, Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations, Bull Cancer, vol.101, pp.958-965, 2014.

J. S. Wilmott, A. M. Menzies, and L. E. Haydu, BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, Br J Cancer, vol.108, pp.924-931, 2013.

L. Heinzerling and M. Baiter, Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations, Br J Cancer, vol.109, pp.2833-2841, 2013.

A. M. Menzies, J. S. Wilmott, G. V. Long, and R. A. Scolyer, Intra-patient heterogeneity of BRAF mutation status: fact or fiction?, Br J Cancer, vol.111, pp.1678-1679, 2014.

A. M. Menzies, T. Lum, and J. S. Wilmott, Intrapatient homogeneity of BRAFV600E expression in melanoma, Am J Surg Pathol, vol.38, pp.377-382, 2014.

A. M. Menzies, L. E. Haydu, and M. S. Carlino, Inter-and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma, PLoS ONE, vol.9, p.85004, 2014.

M. Yancovitz, A. Litterman, and J. Yoon, Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma, PLoS ONE, vol.7, p.29336, 2012.

K. E. Fisher, C. Cohen, M. T. Siddiqui, J. F. Palma, E. H. Lipford et al., Accurate detection of BRAF p. V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays, Hum Pathol, vol.45, pp.2281-2293, 2014.

M. Ilie and P. Hofman, Pitfalls in lung cancer molecular pathology: how to limit them in routine practice, Curr Med Chem, vol.19, pp.2638-2651, 2012.

K. Washetine, E. Long, and V. Hofman, The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm°haring of experience, Ann Pathol, vol.33, pp.386-397, 2013.

P. A. Vanderlaan, N. Yamaguchi, and E. Folch, Success and failure rates of tumor genotyping techniques in routine pathological samples with nonsmall-cell lung cancer, Lung Cancer, vol.84, pp.39-44, 2014.

S. Lassalle, V. Hofman, and M. I. , Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives, Thyroid, vol.19, pp.1239-1248, 2009.

M. Kashani-sabet, Molecular markers in melanoma, Br J Dermatol, vol.170, pp.31-35, 2014.

S. Pakneshan, A. Salajegheh, R. A. Smith, and A. K. Lam, Clinicopathological relevance of BRAF mutations in human cancer, Pathology, vol.45, pp.346-356, 2013.

J. F. Emile, J. Tisserand, and L. Bergougnoux, Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group, BMC Cancer, vol.13, p.472, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00873750

L. V. Kalman, I. M. Lubin, and S. Barker, Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics, Arch Pathol Lab Med, vol.137, pp.983-988, 2013.

C. Marin, A. Beauchet, and D. Capper, Detection of BRAF p. V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility, Arch Pathol Lab Med, vol.138, pp.71-75, 2014.